DeSci innovates the biomedical system through on-chain scientific intellectual property and permissionless markets, driving scientific innovation and the exploration of cures.
Author: @paulkhls
Translation: Vernacular Blockchain
DeSci has been hot lately, and today I want to share how DeSci and BioDAOs currently operate, based on my talk last week at the EFDevcon in Bangkok.
(DeSci super long article).
DeSci 2049 is a vision for future science that combines biotechnology with a permissionless market driven by open scientific data and open access.
We know that Bitcoin achieved permissionless money, and ETH achieved permissionless code.
Many of us invest in cryptocurrencies to protect our autonomy and the freedoms that are being slowly and silently stripped away.
A similar movement is forming in the fields of science and medicine, as our freedoms in innovation, self-experimentation, and dissemination of science are gradually being eroded by a failing biomedical R&D system.
The current system lacks incentives to develop cures. Goldman Sachs downgraded its rating in 2018 for a biopharmaceutical company that developed a cure for hepatitis C, questioning whether curing patients is a 'sustainable business model.'
Deaths caused by prescription opioids continue to rise. What our system needs are lifetime consumers.
Scientists spend too much time looking for funding instead of focusing on researching science. Imagine if software developers spent most of their time finding funding instead of writing code.
Most of the scientific talent in the world has not been fully utilized. We have failed to realize a hopeful and prosperous solarpunk future because we have not upgraded the infrastructure of science and technology. This creates a world filled with scientific friction rather than a world of scientific fantasy.
What if we could build a permissionless scientific world?
Self-sovereign science, defined as driven by open data and fluid markets, aims to find cures.
So, what roles do @Molecule_dao and @bioprotocol play in this?
Molecule is a protocol that brings scientific intellectual property on-chain.
BIO is an engine for launching and accelerating on-chain scientific communities (BioDAOs) composed of scientists, patients, and investors.
BioDAOs build intellectual property (research, drugs, products) based on blockchain, targeting specific scientific fields or diseases.
For example, @vita_dao has funded several projects in the longevity science and research fields, including the VITA-FAST project located at @Vikorolchuk's laboratory at @UniofNewcastle.
More information about VITA-FAST: https://vitafast.xyz
VITAFAST Token: https://coingecko.com/en/coins/molecules-of-korolchuk-ip-nft
Our team helped build the first wave of BioDAOs covering multiple scientific fields. When I gave this talk last week, the total market cap of BioDAOs in our network was less than $100 million. Now it has exceeded $230 million!
Source: https://dune.com/kiba/bioconomy
BIO guides scientists, patients, and biotech founders through the process of bringing the scientific community on-chain, including token economics, community building, funding, liquidity, and more.
BIO holder voting brings DAOs into the network—similar to a community-owned accelerator—allowing the best teams to stand out and launch their communities on-chain.
Upcoming projects will be launched on the BIO Launchpad, including @endrarediseases, @QuantumBioDAO, and @longcovidlabs.
Several new BioDAOs focus on specific patient populations, seeking solutions and new ways to accelerate cures.
Curetopia (@endrarediseases) targets a $1 trillion market for rare diseases, led by @eperlste, a Y-Combinator alumnus, Harvard Ph.D., and rare disease entrepreneur, who advanced a drug to phase 3 clinical trials with only $5 million (far below the typical cost of over $100 million).
https://x.com/bioprotocol/status/1842510500111741056/video/1
Long COVID Labs (@longcovidlabs) is accelerating the search for cures for over 100 million patients worldwide, led by former Stanford neuroscientist @rd108, who self-treated his long COVID.
Today, @longcovidlabs is announcing the start of general eligibility screening for our first study using combination antiviral treatments.
@QuantumBioDAO is developing quantum microscopes to observe quantum biological phenomena, led by MIT Ph.D. @ClariceDAiello, one of the world's leading scientists in quantum biology.
Quantum Biology DAO's @geoffanders discussed the possibility of building quantum microscopes that could unlock the following innovations:
• Wearable devices to accelerate muscle recovery
• Mobile applications for launching cell therapies
• Efficient laboratory-grown meat production
Join @QuantumBioDAO: http://quantumbiology.community
Link to the article: https://www.hellobtc.com/kp/du/11/5540.html
Source: https://x.com/paulkhls/status/1858546224514941269